Cargando…

Why Is There Low Utilization of Biosimilars in Inflammatory Bowel Disease Patients by Gastroenterology Advanced Practice Providers?

AIM: To assess knowledge, practice patterns and attitudes toward the use of biosimilars by Advanced Practice Providers (APPs) treating patients with inflammatory bowel disease (IBD). BACKGROUND: APPs provide care in a variety of healthcare settings including medical specialties. In Gastroenterology,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bernasko, Nana, Clarke, Kofi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Observations and Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9802381/ https://www.ncbi.nlm.nih.gov/pubmed/36777276 http://dx.doi.org/10.1093/crocol/otab004

Ejemplares similares

Editorial Review for: Why Is There Low Utilization of Biosimilars in Inflammatory Bowel Disease Patients by Gastroenterology Advanced Practice Providers?
por: Hanson, Karen
Publicado: (2021)

Impact of a nurse navigator on a dedicated inflammatory bowel disease-focused gastroenterology clinic
por: Maheshwari, Parth, et al.
Publicado: (2021)

COVID-19 Vaccine Hesitancy in Patients with Inflammatory Bowel Disease
por: Clarke, Kofi, et al.
Publicado: (2022)

Real-world data on the infliximab biosimilar CT-P13 (Remsima(®)) in inflammatory bowel disease
por: Huguet, Jose María, et al.
Publicado: (2021)

Symptoms associated with healthcare resource utilization in the setting of inflammatory bowel disease
por: Bogale, Kaleb, et al.
Publicado: (2022)

Improving outpatient care in adult inflammatory bowel disease: effect of implementation of a reminder checklist in the electronic health records (IBD-ERS)—a pilot study
por: Bernasko, Nana, et al.
Publicado: (2023)

Gastrointestinal hypoalgesia in inflammatory bowel disease
por: Coates, Matthew D., et al.
Publicado: (2020)

Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease
por: Guerra Veloz, María Fernanda, et al.
Publicado: (2018)

Switching From Reference Infliximab to Biosimilar CT-P13 Did Not Change Quality of Life in Stable Inflammatory Bowel Disease Patients
por: Pierik, Marieke J, et al.
Publicado: (2021)

Joint Canadian Association of Gastroenterology and Crohn’s Colitis Canada Position Statement on Biosimilars for the Treatment of Inflammatory Bowel Disease
por: Moayyedi, Paul, et al.
Publicado: (2019)

Abdominal Pain and Anxious or Depressed State Are Independently Associated With Weight Loss in Inflammatory Bowel Disease
por: Gorrepati, Venkata Subhash, et al.
Publicado: (2020)

Dedicated Psychiatry Clinic for Inflammatory Bowel Disease Patients Has a Positive Impact on Depression Scores
por: Bogale, Kaleb, et al.
Publicado: (2021)

FOCUS: Future of fecal calprotectin utility study in inflammatory bowel disease
por: Rosenfeld, Greg, et al.
Publicado: (2016)

Utility of Intestinal Ultrasound in Clinical Decision-Making for Inflammatory Bowel Disease
por: Saleh, Adam, et al.
Publicado: (2023)

Biosimilar medicines – their use in the treatment of inflammatory bowel diseases. Position statement of the Working Group of the Polish National Consultant in Gastroenterology
por: Mularczyk, Aldona, et al.
Publicado: (2014)

Disruptive behavior in the workplace: Challenges for gastroenterology fellows
por: Srisarajivakul, Nalinee, et al.
Publicado: (2017)

The Reliability of Patient Self-reported Utilization in an Inflammatory Bowel Diseases Learning Health System
por: van Deen, Welmoed K, et al.
Publicado: (2021)

Assessment of Benefit of Advanced Inflammatory Bowel Disease Training: Challenges and Solutions
por: Cushing, Kelly C, et al.
Publicado: (2020)

Use of Standardized Inflammatory Bowel Disease Endoscopy Scores in Clinical Practice
por: Gaidos, Jill K J, et al.
Publicado: (2023)

Appraisals of Pain in Pediatric Inflammatory Bowel Disease: A Qualitative Study With Youth, Parents, and Providers
por: Gorbounova, Irina, et al.
Publicado: (2022)

Subtle skills: Using objective structured clinical examinations to assess gastroenterology fellow performance in system based practice milestones
por: Papademetriou, Marianna, et al.
Publicado: (2020)

Biosimilars in paediatric inflammatory bowel disease
por: Sieczkowska-Golub, Joanna, et al.
Publicado: (2018)

Transitions of care across hospital settings in patients with inflammatory bowel disease
por: Warren, Leigh R, et al.
Publicado: (2019)

Pregnancy and inflammatory bowel disease: Do we provide enough patient education? A British study of 1324 women
por: Carbery, Isabel, et al.
Publicado: (2016)

A Missing Piece of the Puzzle: Patient and Provider Perspectives on Pain Management Needs and Opioid Prescribing in Inflammatory Bowel Disease Care
por: Balbale, Salva N, et al.
Publicado: (2022)

Fecal Incontinence in Inflammatory Bowel Disease
por: Kamal, Natasha, et al.
Publicado: (2021)

Gastroenterology team members’ knowledge and practices with fertility therapy for women with inflammatory bowel disease
por: Laube, Robyn, et al.
Publicado: (2022)

Nurse-Provided Medication Guidance for Improving Drug Adherence to Thiopurines in Outpatients With Inflammatory Bowel Disease: A Single-Center Prospective Study
por: Shinzaki, Shinichiro, et al.
Publicado: (2021)

Sentinel Cards Provide Practical SARS-CoV-2 Monitoring in School Settings
por: Cantú, Victor J., et al.
Publicado: (2022)

Switching Between Reference Biologics and Biosimilars for the Treatment of Rheumatology, Gastroenterology, and Dermatology Inflammatory Conditions: Considerations for the Clinician
por: Moots, Robert, et al.
Publicado: (2017)

Association Between Inflammatory Bowel Disease and Pruritus
por: Iwamoto, Shiho, et al.
Publicado: (2020)

Opioid Use in Patients With Inflammatory Bowel Disease
por: Lin, Xiwu, et al.
Publicado: (2020)

Economic Burden of Fatigue in Inflammatory Bowel Disease
por: Ananthakrishnan, Ashwin N, et al.
Publicado: (2023)

Natural Transmission of Helicobacter saguini Causes Multigenerational Inflammatory Bowel Disease in C57/129 IL-10(−/−) Mice
por: Mannion, Anthony, et al.
Publicado: (2020)

Benefits of implementing a rapid access clinic in a high-volume inflammatory bowel disease center: Access, resource utilization and outcomes
por: Nene, Sofia, et al.
Publicado: (2020)

Perceptions towards biologic and biosimilar therapy of patients with rheumatic and gastroenterological conditions
por: Khoo, Thomas, et al.
Publicado: (2022)

Low Health Literacy Exists in the Inflammatory Bowel Disease (IBD) Population and Is Disproportionately Prevalent in Older African Americans
por: Dos Santos Marques, Isabel C, et al.
Publicado: (2020)

High Burden of Obesity and Low Rates of Weight Loss Pharmacotherapy in Inflammatory Bowel Disease: 10-Year Trend
por: Elangovan, Abbinaya, et al.
Publicado: (2023)

Advanced small-bowel well-differentiated neuroendocrine tumours: An international survey of practice on 3(rd)-line treatment
por: Lamarca, Angela, et al.
Publicado: (2021)

Reclassifying Pseudopolyps in Inflammatory Bowel Disease: Histologic and Endoscopic Description in the New Era of Mucosal Healing
por: Rezapour, Mona, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_iqgiakl1lubvtgc27p6ni1n3sg